166 related articles for article (PubMed ID: 10781850)
1. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
[TBL] [Abstract][Full Text] [Related]
2. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.
Goetsch L; Plotnicky-Gilquin H; Champion T; Beck A; Corvaïa N; Stâhl S; Bonnefoy JY; Nguyen TN; Power UF
Vaccine; 2000 Jun; 18(24):2735-42. PubMed ID: 10781861
[TBL] [Abstract][Full Text] [Related]
3. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
[TBL] [Abstract][Full Text] [Related]
4. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides.
Cano F; Plotnicky-Gilquin H; Nguyen TN; Liljeqvist S; Samuelson P; Bonnefoy J; Stâhl S; Robert A
Vaccine; 2000 Jun; 18(24):2743-52. PubMed ID: 10781862
[TBL] [Abstract][Full Text] [Related]
5. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
[TBL] [Abstract][Full Text] [Related]
6. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
[TBL] [Abstract][Full Text] [Related]
7. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide.
Corvaïa N; Tournier P; Nguyen TN; Haeuw JF; Power UF; Binz H; Andréoni C
J Infect Dis; 1997 Sep; 176(3):560-9. PubMed ID: 9291300
[TBL] [Abstract][Full Text] [Related]
8. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
Murphy BR; Walsh EE
J Clin Microbiol; 1988 Aug; 26(8):1595-7. PubMed ID: 2459154
[TBL] [Abstract][Full Text] [Related]
9. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies.
Siegrist CA; Plotnicky-Gilquin H; Córdova M; Berney M; Bonnefoy JY; Nguyen TN; Lambert PH; Power UF
J Infect Dis; 1999 Jun; 179(6):1326-33. PubMed ID: 10228051
[TBL] [Abstract][Full Text] [Related]
10. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
11. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein.
Libon C; Corvaïa N; Haeuw JF; Nguyen TN; Ståhl S; Bonnefoy JY; Andreoni C
Vaccine; 1999 Feb; 17(5):406-14. PubMed ID: 10073717
[TBL] [Abstract][Full Text] [Related]
12. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.
Plotnicky-Gilquin H; Robert A; Chevalet L; Haeuw JF; Beck A; Bonnefoy JY; Brandt C; Siegrist CA; Nguyen TN; Power UF
J Virol; 2000 Apr; 74(8):3455-63. PubMed ID: 10729118
[TBL] [Abstract][Full Text] [Related]
13. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.
Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G
J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323
[TBL] [Abstract][Full Text] [Related]
14. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
15. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
Murphy BR; Olmsted RA; Collins PL; Chanock RM; Prince GA
J Virol; 1988 Oct; 62(10):3907-10. PubMed ID: 3047432
[TBL] [Abstract][Full Text] [Related]
16. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
[TBL] [Abstract][Full Text] [Related]
17. BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice.
Goetsch L; Plotnicky-Gilquin H; Aubry JP; De-Lys P; Haeuw JF; Bonnefoy JY; Nguyen NT; Corvaïa N; Velin D
Vaccine; 2001 Jul; 19(28-29):4036-42. PubMed ID: 11427280
[TBL] [Abstract][Full Text] [Related]
18. Passive transfer of serum antibodies induced by BBG2Na, a subunit vaccine, in the elderly protects SCID mouse lungs against respiratory syncytial virus challenge.
Plotnicky-Gilquin H; Cyblat-Chanal D; Goetsch L; Lacheny C; Libon C; Champion T; Beck A; Pasche H; Nguyen TN; Bonnefoy JY; Bouveret-le-Cam N; Corvaïa N
Virology; 2002 Nov; 303(1):130-7. PubMed ID: 12482664
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein.
Power UF; Plotnicky-Gilquin H; Goetsch L; Champion T; Beck A; Haeuw JF; Nguyen TN; Bonnefoy JY; Corvaïa N
Vaccine; 2001 Mar; 19(17-19):2345-51. PubMed ID: 11257359
[TBL] [Abstract][Full Text] [Related]
20. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.
Plotnicky-Gilquin H; Goetsch L; Huss T; Champion T; Beck A; Haeuw JF; Nguyen TN; Bonnefoy JY; Corvaïa N; Power UF
J Virol; 1999 Jul; 73(7):5637-45. PubMed ID: 10364313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
